IntelGenx Technologies

IGXT · TORONTO

Price unavailable right now.

No price history for this range.

About IGXT

IntelGenx Technologies Corp. is a drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. The company is headquartered in Saint-Laurent, Quebec. The Company’s film technologies, including VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, allow for pharmaceutical products that address unmet medical needs. Its VersaFilm is a drug delivery platform technology that enables the development of oral thin films. Its VetaFilm platform technology is designed for the application in companion animals. Its transdermal VevaDerm is a fully integrated solution provider for drug-in-adhesive transdermal products. Its product pipeline offers benefits to patients and physicians for many therapeutic conditions. The company provides pharmaceutical services to pharmaceutical partners, including research and development, analytical method development, clinical monitoring, intellectual property and regulatory services. Its manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production.

Employees
50
Headquarters
Saint-Laurent, Quebec
Listed
May 23, 2008
Sector
Health Care
Industry
Pharmaceuticals

IGXT key statistics

This section is temporarily unavailable. Refresh to try again.

IGXT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 1.0% on average.

  1. Q3 FY19: reported -$0.03 per share against an estimate of -$0.0303
  2. Q4 FY19: reported -$0.03 per share against an estimate of -$0.0303
  3. Q1 FY20: reported -$0.03 per share against an estimate of -$0.0202
  4. Q4 FY22: reported -$0.02 per share against an estimate of $0.00
  5. Q1 FY23: reported -$0.02 per share against an estimate of $0.00
  6. Q2 FY23: reported -$0.02 per share against an estimate of $0.00
  7. Q3 FY23: reported -$0.01 per share against an estimate of $0.00
  8. Q4 FY23: reported -$0.02 per share against an estimate of $0.00

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.